AR and neoplasm: Of the 5 LAR samples classified as non-basal-like, 4 were HER2-enriched and 1 was luminal A. We had enough tumor tissue to successfully determine the expression of the androgen receptor (AR) in the luminal A and three out of four HER2-enriched tumors; all overexpressed AR and were histopathologically consistent with apocrine carcinomas.